Comparison of purity and enrichment of CD34+ cells from bone marrow, umbilical cord and peripheral blood (primed for apheresis) using five separation systems
- PMID: 8528102
- DOI: 10.1002/stem.5530130510
Comparison of purity and enrichment of CD34+ cells from bone marrow, umbilical cord and peripheral blood (primed for apheresis) using five separation systems
Abstract
Interest in the isolation and characterization of primitive hemopoietic cells in both the clinical and research fields has rapidly increased. In parallel, different purification systems have been developed to isolate these cells. We have compared five different methods for separation of CD34+ cells from human umbilical cord blood, normal bone marrow and apheresis harvests and analyzed purity, recovery, yield and enrichment of colony forming cells (CFC) for each individual system. Our results indicate that the most reliable methods of purification for all samples were fluorescence activated cell sorting (FACS) and magnetic activated cell sorting (MACS) which consistently yielded high purities (> 70%) and enrichment of CFC. In this respect the enrichment of CFC from the MACS was superior to all the other systems including FACS. Similar results (> 70%) for purity were obtained using avidin affinity columns and a biotinylated antibody but neither yield nor CFC enrichment approached the values achieved with MACS. On average CFC enrichment using these affinity columns was greater than that observed for FACS while the purity was comparable. Both CELLector flasks and immunomagnetic beads coated with CD34 antibodies were less effective in our hands in separating purified populations of progenitor cells. Both purity and CFC enrichment of CD34+ cells using these methods were at least 50% lower than obtained with either FACS, MACS or affinity columns.
Similar articles
-
Harvesting, characterization, and culture of CD34+ cells from human bone marrow, peripheral blood, and cord blood.Blood Cells. 1994;20(2-3):411-23. Blood Cells. 1994. PMID: 7538347
-
Multicentre European study comparing selection techniques for the isolation of CD34+ cells.Bone Marrow Transplant. 1999 Jun;23(11):1191-6. doi: 10.1038/sj.bmt.1701789. Bone Marrow Transplant. 1999. PMID: 10382960
-
Two CD34+ stem cells from umbilical cord blood enrichment methods.Pediatr Hematol Oncol. 2002 Jun;19(4):239-45. doi: 10.1080/08880010252899406. Pediatr Hematol Oncol. 2002. PMID: 12051590
-
CD34+ selected cells in clinical transplantation.Stem Cells. 1994 Nov;12(6):577-85. doi: 10.1002/stem.5530120605. Stem Cells. 1994. PMID: 7533577 Review.
-
CD34+ progenitor cell selection: clinical transplantation, tumor cell purging, gene therapy, ex vivo expansion, and cord blood processing.J Hematother. 1996 Apr;5(2):179-84. doi: 10.1089/scd.1.1996.5.179. J Hematother. 1996. PMID: 8723797 Review.
Cited by
-
Effect of platelet-activating factor on the growth of human erythroid and myeloid CD34+ progenitors.Mediators Inflamm. 1998;7(2):99-103. doi: 10.1080/09629359891243. Mediators Inflamm. 1998. PMID: 9836496 Free PMC article.
-
CD52/FLAG and CD52/HA Fusion Proteins as Novel Magnetic Cell Selection Markers.Int J Mol Sci. 2024 Jun 8;25(12):6353. doi: 10.3390/ijms25126353. Int J Mol Sci. 2024. PMID: 38928060 Free PMC article.
-
How do I perform hematopoietic progenitor cell selection?Transfusion. 2016 May;56(5):1008-12. doi: 10.1111/trf.13534. Epub 2016 Feb 25. Transfusion. 2016. PMID: 26919388 Free PMC article. Review.
-
Characteristics of human dendritic cells generated in a microgravity analog culture system.In Vitro Cell Dev Biol Anim. 2001 Apr;37(4):216-22. doi: 10.1007/BF02577532. In Vitro Cell Dev Biol Anim. 2001. PMID: 11409686
-
Targeting cancer stem cell pathways for cancer therapy.Signal Transduct Target Ther. 2020 Feb 7;5(1):8. doi: 10.1038/s41392-020-0110-5. Signal Transduct Target Ther. 2020. PMID: 32296030 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous